Cerebrospinal fluid abnormalities and rate of decline in everyday function across the dementia spectrum: Normal aging, mild cognitive impairment, and Alzheimer disease

Ozioma C. Okonkwo, Michael L. Alosco, H. Randall Griffith, Michelle M Mielke, Leslie M. Shaw, John Q. Trojanowski, Geoffrey Tremont

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Objective: To investigate the effect of cerebrospinal fluid (CSF) abnormalities on the rate of decline in everyday function in normal aging, mild cognitive impairment (MCI), and mild Alzheimer disease (AD). Design: Immunoassays of total tau (t-tau), tau phosphorylated at threonine 181 (p-tau181), and β-amyloid 1-42 (Aβ42) concentrations were performed in CSF obtained from participants in the Alzheimer's Disease Neuroimaging Initiative. Random effects regressions were used to examine the relationship among CSF abnormalities, cognitive impairment (assessed with the Alzheimer Disease Assessment Scale-cognitive subscale [ADAS-Cog]), and functional decline (assessed with the Pfeffer Functional Activities Questionnaire) and to determine whether the impact of CSF abnormalities on functional decline is mediated by cognitive impairment. Setting: Fifty-eight sites in the United States andCanada. Participants: One hundred fourteen cognitively intact adults, 195 patients with MCI, and 100 patients with mild AD. Main Outcome Measure: Decline in the Pfeffer Functional Activities Questionnaire score. Results: Abnormalities in all CSF analytes were associated with functional decline in MCI, and all but the t-tau: Aβ42 ratio were associated with functional decline in controls. No abnormal CSF analyte was associated with functional decline in AD. Among controls, p-tau181 concentration was the most sensitive to functional decline, whereas in MCI it was Aβ42 concentration. Cerebrospinal fluid biomarkers were uniformly more sensitive to functional decline than the ADAS-Cog score among controls and variably so in MCI, whereas the ADAS-Cog score was unequivocally more sensitive than CSF biomarkers in AD. The impact of CSF abnormalities on functional decline in MCI was partially mediated by their effect on cognitive status. Across all diagnostic groups, persons with both tau and Aβ42 abnormalities exhibited the steepest rate of functional decline. Conclusions: Abnormalities in CSF are associated with functional decline and thus with future development of AD in controls and patients with MCI. However, they do not predict further functional degradation in patients with AD. Persons with comorbid tau and Aβ42 abnormalities are at greatest risk of functional loss.

Original languageEnglish (US)
Pages (from-to)688-696
Number of pages9
JournalArchives of Neurology
Volume67
Issue number6
DOIs
StatePublished - Jun 2010
Externally publishedYes

Fingerprint

Cerebrospinal Fluid
Dementia
Alzheimer Disease
Amyloid
Biomarkers
Cognitive Dysfunction
Alzheimer's Disease
Mild Cognitive Impairment
Threonine
Immunoassay
Neuroimaging
Outcome Assessment (Health Care)

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Cerebrospinal fluid abnormalities and rate of decline in everyday function across the dementia spectrum : Normal aging, mild cognitive impairment, and Alzheimer disease. / Okonkwo, Ozioma C.; Alosco, Michael L.; Griffith, H. Randall; Mielke, Michelle M; Shaw, Leslie M.; Trojanowski, John Q.; Tremont, Geoffrey.

In: Archives of Neurology, Vol. 67, No. 6, 06.2010, p. 688-696.

Research output: Contribution to journalArticle

Okonkwo, Ozioma C. ; Alosco, Michael L. ; Griffith, H. Randall ; Mielke, Michelle M ; Shaw, Leslie M. ; Trojanowski, John Q. ; Tremont, Geoffrey. / Cerebrospinal fluid abnormalities and rate of decline in everyday function across the dementia spectrum : Normal aging, mild cognitive impairment, and Alzheimer disease. In: Archives of Neurology. 2010 ; Vol. 67, No. 6. pp. 688-696.
@article{ae3d75f0f9ed4d94a626f535c5858674,
title = "Cerebrospinal fluid abnormalities and rate of decline in everyday function across the dementia spectrum: Normal aging, mild cognitive impairment, and Alzheimer disease",
abstract = "Objective: To investigate the effect of cerebrospinal fluid (CSF) abnormalities on the rate of decline in everyday function in normal aging, mild cognitive impairment (MCI), and mild Alzheimer disease (AD). Design: Immunoassays of total tau (t-tau), tau phosphorylated at threonine 181 (p-tau181), and β-amyloid 1-42 (Aβ42) concentrations were performed in CSF obtained from participants in the Alzheimer's Disease Neuroimaging Initiative. Random effects regressions were used to examine the relationship among CSF abnormalities, cognitive impairment (assessed with the Alzheimer Disease Assessment Scale-cognitive subscale [ADAS-Cog]), and functional decline (assessed with the Pfeffer Functional Activities Questionnaire) and to determine whether the impact of CSF abnormalities on functional decline is mediated by cognitive impairment. Setting: Fifty-eight sites in the United States andCanada. Participants: One hundred fourteen cognitively intact adults, 195 patients with MCI, and 100 patients with mild AD. Main Outcome Measure: Decline in the Pfeffer Functional Activities Questionnaire score. Results: Abnormalities in all CSF analytes were associated with functional decline in MCI, and all but the t-tau: Aβ42 ratio were associated with functional decline in controls. No abnormal CSF analyte was associated with functional decline in AD. Among controls, p-tau181 concentration was the most sensitive to functional decline, whereas in MCI it was Aβ42 concentration. Cerebrospinal fluid biomarkers were uniformly more sensitive to functional decline than the ADAS-Cog score among controls and variably so in MCI, whereas the ADAS-Cog score was unequivocally more sensitive than CSF biomarkers in AD. The impact of CSF abnormalities on functional decline in MCI was partially mediated by their effect on cognitive status. Across all diagnostic groups, persons with both tau and Aβ42 abnormalities exhibited the steepest rate of functional decline. Conclusions: Abnormalities in CSF are associated with functional decline and thus with future development of AD in controls and patients with MCI. However, they do not predict further functional degradation in patients with AD. Persons with comorbid tau and Aβ42 abnormalities are at greatest risk of functional loss.",
author = "Okonkwo, {Ozioma C.} and Alosco, {Michael L.} and Griffith, {H. Randall} and Mielke, {Michelle M} and Shaw, {Leslie M.} and Trojanowski, {John Q.} and Geoffrey Tremont",
year = "2010",
month = "6",
doi = "10.1001/archneurol.2010.118",
language = "English (US)",
volume = "67",
pages = "688--696",
journal = "Archives of Neurology",
issn = "0003-9942",
publisher = "American Medical Association",
number = "6",

}

TY - JOUR

T1 - Cerebrospinal fluid abnormalities and rate of decline in everyday function across the dementia spectrum

T2 - Normal aging, mild cognitive impairment, and Alzheimer disease

AU - Okonkwo, Ozioma C.

AU - Alosco, Michael L.

AU - Griffith, H. Randall

AU - Mielke, Michelle M

AU - Shaw, Leslie M.

AU - Trojanowski, John Q.

AU - Tremont, Geoffrey

PY - 2010/6

Y1 - 2010/6

N2 - Objective: To investigate the effect of cerebrospinal fluid (CSF) abnormalities on the rate of decline in everyday function in normal aging, mild cognitive impairment (MCI), and mild Alzheimer disease (AD). Design: Immunoassays of total tau (t-tau), tau phosphorylated at threonine 181 (p-tau181), and β-amyloid 1-42 (Aβ42) concentrations were performed in CSF obtained from participants in the Alzheimer's Disease Neuroimaging Initiative. Random effects regressions were used to examine the relationship among CSF abnormalities, cognitive impairment (assessed with the Alzheimer Disease Assessment Scale-cognitive subscale [ADAS-Cog]), and functional decline (assessed with the Pfeffer Functional Activities Questionnaire) and to determine whether the impact of CSF abnormalities on functional decline is mediated by cognitive impairment. Setting: Fifty-eight sites in the United States andCanada. Participants: One hundred fourteen cognitively intact adults, 195 patients with MCI, and 100 patients with mild AD. Main Outcome Measure: Decline in the Pfeffer Functional Activities Questionnaire score. Results: Abnormalities in all CSF analytes were associated with functional decline in MCI, and all but the t-tau: Aβ42 ratio were associated with functional decline in controls. No abnormal CSF analyte was associated with functional decline in AD. Among controls, p-tau181 concentration was the most sensitive to functional decline, whereas in MCI it was Aβ42 concentration. Cerebrospinal fluid biomarkers were uniformly more sensitive to functional decline than the ADAS-Cog score among controls and variably so in MCI, whereas the ADAS-Cog score was unequivocally more sensitive than CSF biomarkers in AD. The impact of CSF abnormalities on functional decline in MCI was partially mediated by their effect on cognitive status. Across all diagnostic groups, persons with both tau and Aβ42 abnormalities exhibited the steepest rate of functional decline. Conclusions: Abnormalities in CSF are associated with functional decline and thus with future development of AD in controls and patients with MCI. However, they do not predict further functional degradation in patients with AD. Persons with comorbid tau and Aβ42 abnormalities are at greatest risk of functional loss.

AB - Objective: To investigate the effect of cerebrospinal fluid (CSF) abnormalities on the rate of decline in everyday function in normal aging, mild cognitive impairment (MCI), and mild Alzheimer disease (AD). Design: Immunoassays of total tau (t-tau), tau phosphorylated at threonine 181 (p-tau181), and β-amyloid 1-42 (Aβ42) concentrations were performed in CSF obtained from participants in the Alzheimer's Disease Neuroimaging Initiative. Random effects regressions were used to examine the relationship among CSF abnormalities, cognitive impairment (assessed with the Alzheimer Disease Assessment Scale-cognitive subscale [ADAS-Cog]), and functional decline (assessed with the Pfeffer Functional Activities Questionnaire) and to determine whether the impact of CSF abnormalities on functional decline is mediated by cognitive impairment. Setting: Fifty-eight sites in the United States andCanada. Participants: One hundred fourteen cognitively intact adults, 195 patients with MCI, and 100 patients with mild AD. Main Outcome Measure: Decline in the Pfeffer Functional Activities Questionnaire score. Results: Abnormalities in all CSF analytes were associated with functional decline in MCI, and all but the t-tau: Aβ42 ratio were associated with functional decline in controls. No abnormal CSF analyte was associated with functional decline in AD. Among controls, p-tau181 concentration was the most sensitive to functional decline, whereas in MCI it was Aβ42 concentration. Cerebrospinal fluid biomarkers were uniformly more sensitive to functional decline than the ADAS-Cog score among controls and variably so in MCI, whereas the ADAS-Cog score was unequivocally more sensitive than CSF biomarkers in AD. The impact of CSF abnormalities on functional decline in MCI was partially mediated by their effect on cognitive status. Across all diagnostic groups, persons with both tau and Aβ42 abnormalities exhibited the steepest rate of functional decline. Conclusions: Abnormalities in CSF are associated with functional decline and thus with future development of AD in controls and patients with MCI. However, they do not predict further functional degradation in patients with AD. Persons with comorbid tau and Aβ42 abnormalities are at greatest risk of functional loss.

UR - http://www.scopus.com/inward/record.url?scp=77953628344&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953628344&partnerID=8YFLogxK

U2 - 10.1001/archneurol.2010.118

DO - 10.1001/archneurol.2010.118

M3 - Article

C2 - 20558388

AN - SCOPUS:77953628344

VL - 67

SP - 688

EP - 696

JO - Archives of Neurology

JF - Archives of Neurology

SN - 0003-9942

IS - 6

ER -